Goldman Sachs’s Zenas BioPharma ZBIO Stock Holding History

Goldman Sachs’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.88M	Sell	271,163 -110,298	-29%	-$2.19M	﹤0.01%	3589
2026 Q1	$7.46M	Buy	381,461 +250,763	+192%	+$5.63M	﹤0.01%	3318
2025 Q4	$4.75M	Buy	+130,698	New	+$4.3M	﹤0.01%	3793
2025 Q2	–	Sell	-23,957	Closed	-$189K	–	6526
2025 Q1	$189K	Sell	23,957 -18,217	-43%	-$143K	﹤0.01%	5655
2024 Q4	$345K	Sell	42,174 -90,226	-68%	-$1.41M	﹤0.01%	5435
2024 Q3	$2.24M	Buy	+132,400	New	+$2.38M	﹤0.01%	4064

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Goldman Sachs's ZBIO Position: Q2 2026 in Review

Goldman Sachs reduced its Zenas BioPharma (ZBIO) stake by 29% in Q2 2026, selling an estimated $2.19M and leaving 271,163 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

Goldman Sachs first reported a position in ZBIO in Q3 2024 and has held it in 6 quarters since. The position peaked at $7.46M in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Goldman Sachs held 271,163 shares of Zenas BioPharma worth $6.88M as of Q2 2026.
Goldman Sachs sold 110,298 Zenas BioPharma shares in Q2 2026, an estimated $2.19M.
Zenas BioPharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3589 holding.
Goldman Sachs first reported a position in Zenas BioPharma in Q3 2024 and has held it in 6 quarters since.
Goldman Sachs's Zenas BioPharma position peaked at $7.46M in Q1 2026.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.